Noninvasive tests have the potential to significantly enhance the care of patients with nonalcoholic fatty liver disease (NAFLD) by improving detection of advanced fibrosis, according to the American Gastroenterological Association.
A Swedish study found that 11.8% of patients with inflammatory bowel disease (IBD) were diagnosed with chronic kidney disease (CKD) within 10 years, and their risks of acute kidney injury and kidney stones were also elevated.
A trial in Asia found that automated calculation of fibrosis scores and electronic reminder messages to clinicians increased referrals of patients with abnormal results to appropriate care, although subsequent diagnosis of advanced liver disease was uncommon.
A 35-year-old woman is evaluated for nocturnal heartburn and regurgitation. She has a 5-year history of gastroesophageal reflux disease. She takes omeprazole every day 30 minutes before breakfast. Following a physical exam, what is the most appropriate additional management?
An update of ACP's 2019 guidance statement on the topic suggests that clinicians start screening for colorectal cancer in asymptomatic average-risk adults at age 50 years and consider not screening those between the ages of 45 and 49 years.
While patients who took proton-pump inhibitors (PPIs) from mid- to late life had a modestly higher risk of dementia in late life versus nonusers, shorter-term use was not associated with increased risk.
Researchers have found innovative ways to improve hospital systems for diagnosing Clostridioides difficile.
A comparison in which some patients with malignant small bowel obstruction were randomized and some chose between surgery and nonsurgical management found no difference in mortality between treatments, but surgery was associated with more symptom improvement.
An infectious diseases specialist and a gastroenterologist discussed antibiotic treatment options for nonsevere Clostridioides difficile in a recent Beyond the Guidelines.
Two unusual cases of pouchitis occurred in older men receiving therapy for esophageal squamous cell carcinoma and hepatocellular carcinoma.